医学
危险系数
外科肿瘤学
比例危险模型
化疗
淋巴结
辅助化疗
外科
肝内胆管癌
内科学
肿瘤科
癌症
置信区间
乳腺癌
作者
Laura Alaimo,Zorays Moazzam,Zachary J. Brown,Yutaka Endo,Andrea Ruzzenente,Alfredo Guglielmi,Luca Aldrighetti,Matthew J. Weiss,Todd W. Bauer,Sorin Alexandrescu,George A. Poultsides,Shishir K. Maithel,Hugo P. Marques,Guillaume Martel,Carlo Pulitanò,Feng Shen,Olivier Soubrane,Bas Groot Koerkamp,Itaru Endo,Timothy M. Pawlik
标识
DOI:10.1245/s10434-022-12463-7
摘要
PurposeTo investigate recurrence patterns after surgery for intrahepatic cholangiocarcinoma (ICC) relative to lymph node status, tumor extension, tumor burden score (TBS), and adjuvant chemotherapy.MethodsPatients who underwent curative-intent resection for ICC from 1990 to 2020 were enrolled from a multi-institutional database. The hazard function was applied to plot the hazard rates over time, with further stratification by T and N AJCC 8th edition categories, TBS, and adjuvant chemotherapy.ResultsA total of 1192 patients underwent curative-intent resection for ICC and 59.9% experienced recurrence. Overall, the peak of recurrence occurred at 6.6 months. Among patients with negative lymph nodes, the T4-category had a higher peak rate of recurrence (0.1199 at 10.2 months) compared with other T-categories, while high TBS had an earlier peak of recurrence (4.2 months) compared with lower TBS. Among patients with N1 disease, T2–T4 categories had multipeak patterns of recurrence with higher hazard rates during the first 3 years after surgery in comparison with T1-category, while patients with high TBS had an earlier (4.0 months) and higher hazard peak rate compared with lower TBS groups. The administration of adjuvant chemotherapy was associated with delayed hazard rates of recurrence for N1 (4 months) and NX (6 months) categories.DiscussionThe novel application of the hazard function to assess hazard rates and timing patterns of recurrence following resection for ICC demonstrated that recurrence varied based on T- and N-categories, as well as TBS. Hazard function-based recurrence data may be helpful to tailor counseling, surveillance, and adjuvant therapy recommendations.
科研通智能强力驱动
Strongly Powered by AbleSci AI